SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-042407
Filing Date
2023-08-14
Accepted
2023-08-14 16:09:34
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acer-20230814.htm   iXBRL 8-K 69128
2 EX-99.1 acer-ex99_1.htm EX-99.1 280591
3 GRAPHIC img104994230_0.jpg GRAPHIC 3553
  Complete submission text file 0000950170-23-042407.txt   495521

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acer-20230814_pre.xml EX-101.PRE 11534
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acer-20230814_lab.xml EX-101.LAB 18344
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acer-20230814.xsd EX-101.SCH 2458
8 EXTRACTED XBRL INSTANCE DOCUMENT acer-20230814_htm.xml XML 4902
Mailing Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458
Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458 (844) 902-6100
Acer Therapeutics Inc. (Filer) CIK: 0001069308 (see all company filings)

IRS No.: 320426967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33004 | Film No.: 231170090
SIC: 2834 Pharmaceutical Preparations